Toxoplasmosis in Cats: Zoonotic Risk, Fecal Shedding, and Prevention

Introduction

Toxoplasmosis is a globally distributed parasitic zoonosis caused by the obligate intracellular apicomplexan protozoan Toxoplasma gondii [1, 2]. Felids, including domestic cats (Felis catus), serve as the definitive hosts in which the parasite completes its sexual cycle and produces environmentally resistant oocysts that are shed in feces [2, 3]. The infection is of major veterinary and public health concern because oocyst shedding from cats contaminates soil, water, and food, leading to infection in intermediate hosts including humans and a wide range of warm-blooded animals [4, 5, 6]. This article provides a detailed, evidence-based review of the etiology, epidemiology, clinical manifestations, diagnostic approaches, and prevention of toxoplasmosis in cats, with emphasis on zoonotic risk and fecal shedding dynamics.

Etiology and Life Cycle

Toxoplasma gondii exists in three infectious stages: tachyzoites (rapidly dividing forms), bradyzoites (slowly dividing forms within tissue cysts), and sporozoites (within sporulated oocysts) [1, 2]. The life cycle is heteroxenous, with sexual reproduction occurring exclusively in the feline intestinal epithelium [2, 7]. After ingestion of tissue cysts (from infected prey) or sporulated oocysts (from environmental contamination), the parasite invades enterocytes and undergoes a series of asexual and sexual developmental stages culminating in the formation of unsporulated oocysts that are shed in feces [1, 2]. Shedding typically begins 3 to 10 days post-infection and can last 1 to 3 weeks, with millions of oocysts excreted daily [2, 3]. Once shed, oocysts sporulate in the environment within 1 to 5 days under suitable conditions of temperature and humidity, becoming infectious [4, 8]. Sporulated oocysts are remarkably resilient, surviving for months to years in soil and water [4, 8].

Epidemiology and Zoonotic Risk

Seroprevalence of T. gondii in domestic cats varies widely by geographic region, management practices, and sampling methodology. Studies report seropositivity rates ranging from 10% to over 60% in different populations [9, 3, 10]. For example, a study in Hong Kong found seroprevalence of 37.5% in privately-owned cats and 45.2% in community cats [9]. In Jordan, seroprevalence was 41.3% with molecular detection of T. gondii DNA in 18.7% of fecal samples [3]. Stray cats in Bangkok showed a 12.5% PCR positivity rate in feces [8]. These data underscore the substantial reservoir of infection in feline populations.

The zoonotic risk arises primarily from ingestion of sporulated oocysts shed in cat feces [4, 11]. Humans can become infected through direct contact with contaminated litter boxes, soil, or water, or indirectly via consumption of unwashed vegetables or undercooked meat from infected intermediate hosts [4, 5, 6]. Oocyst contamination of the environment is a key driver of human infection, particularly in settings with poor sanitation and high cat densities [4, 12]. Veterinary professionals and cat owners are at increased occupational exposure risk [12, 13]. Pregnant women and immunocompromised individuals are especially vulnerable to severe outcomes such as congenital toxoplasmosis and cerebral toxoplasmosis [14, 15, 11].

Fecal Shedding and Environmental Contamination

The term "toxoplasmosis in cat poop" refers to the critical role of feline feces in parasite transmission. Only cats shed oocysts, and primary infection (or reactivation) leads to a brief but intense shedding period [2, 3]. Oocyst excretion is influenced by host immunity, parasite strain, and co-infections [2, 7]. A single cat can excrete up to 100 million oocysts during the patent period [2]. Once sporulated, oocysts are highly resistant to environmental degradation and common disinfectants [4, 8]. They can remain viable in moist soil for over a year and in water for several months [4]. This environmental persistence poses a sustained risk for human and animal exposure, especially in areas with free-roaming cat populations [4, 8, 6].

Pathogenesis and Clinical Signs

Acute and Subclinical Infection

Most cats infected with T. gondii remain asymptomatic [3, 10]. Subclinical infection is common, with seropositive cats showing no overt signs [9, 10]. When clinical disease occurs, it is often associated with immunosuppression (e.g., feline leukemia virus or feline immunodeficiency virus co-infection) or concurrent disease [16]. Clinical signs include fever, lethargy, anorexia, lymphadenopathy, and ocular lesions (uveitis, retinitis) [16, 10].

Neurological Manifestations: Cat Toxoplasmosis Brain

The phrase "cat toxoplasmosis brain" refers to the neurological form of toxoplasmosis in cats, which results from tachyzoite proliferation in the central nervous system (CNS) [15, 17, 18]. Cerebral toxoplasmosis manifests as seizures, ataxia, circling, head pressing, behavioral changes, and cranial nerve deficits [15, 16, 18]. Histopathologically, lesions consist of necrotizing encephalitis with perivascular cuffing, gliosis, and intralesional tachyzoites or tissue cysts [15, 16]. The parasite can also cause myelitis and meningitis [15]. Neurological signs may be acute or progressive, and diagnosis requires a high index of suspicion, especially in immunocompromised cats [16, 18]. The ability of T. gondii to alter host behavior (e.g., reduced fear of predators in rodents) has been documented, but similar behavioral effects in cats are less clear [18].

Ocular and Systemic Disease

Ocular toxoplasmosis is a common manifestation in cats, presenting as anterior uveitis, chorioretinitis, and vitritis [19, 16]. Ocular lesions may be unilateral or bilateral and can lead to blindness if untreated [19]. Systemic disease can involve the lungs (interstitial pneumonia), liver (hepatitis), pancreas (pancreatitis), and heart (myocarditis) [16]. Fatal disseminated toxoplasmosis is rare but reported, particularly in kittens and immunocompromised adults [16].

Diagnostics

Diagnosis of feline toxoplasmosis relies on a combination of serological, molecular, and histopathological methods. A diagnostic workflow is presented in Figure 1.

flowchart TD
    A[Clinical suspicion: neurological, ocular, systemic signs], > B{Serology: IgG/IgM ELISA or IFAT}
    B, >|Positive IgM or rising IgG| C[Confirm with PCR on blood, CSF, or tissue]
    B, >|Negative| D[Consider other etiologies]
    C, >|Positive| E[Diagnosis confirmed: acute or reactivated toxoplasmosis]
    C, >|Negative| F[Consider histopathology or bioassay]
    F, > G[Histopathology: tachyzoites/cysts in tissue sections]
    G, >|Positive| E
    G, >|Negative| H[Rule out toxoplasmosis]
    E, > I[Treatment: clindamycin, trimethoprim-sulfonamide]
    I, > J[Monitor clinical response and serology]

Figure 1. Diagnostic algorithm for feline toxoplasmosis.

Serological Methods

Serological detection of anti-T. gondii antibodies is the most common screening tool. Commercial ELISA kits and indirect fluorescent antibody tests (IFAT) detect IgG and IgM [20, 21, 9]. IgM positivity indicates recent infection or reactivation, while IgG reflects past exposure [9, 3]. A four-fold rise in IgG titers over 2 to 4 weeks supports active infection [9]. Colloidal gold immunochromatographic strips have been developed for rapid serological testing in multiple species, including cats [20, 21]. These point-of-care tests offer high sensitivity and specificity for field use [20, 21].

Molecular Detection

PCR assays targeting T. gondii DNA (e.g., B1 gene, 529 bp repeat element) are highly sensitive and specific for detecting the parasite in blood, cerebrospinal fluid (CSF), aqueous humor, and tissues [8, 3, 22]. Antisense PCR has been developed to improve detection in feline samples [22]. Fecal PCR can identify oocyst shedding, but sensitivity is limited by intermittent excretion and PCR inhibitors in feces [8, 3]. Real-time PCR allows quantification of parasite burden [22].

Histopathology and Immunohistochemistry

Definitive diagnosis of toxoplasmosis can be made by identifying tachyzoites or tissue cysts in biopsy or necropsy specimens [15, 16]. Immunohistochemical staining using anti-T. gondii antibodies enhances detection [15, 16]. Histopathological examination of brain, eye, lung, and lymph nodes is particularly valuable in fatal cases [15, 16].

Treatment and Prevention

Antiparasitic Therapy

The standard treatment for clinical feline toxoplasmosis is clindamycin (10-12 mg/kg orally or intramuscularly every 12 hours for 2-4 weeks) [16]. Alternative regimens include trimethoprim-sulfonamide combinations (15 mg/kg every 12 hours) or pyrimethamine plus a sulfonamide [16]. Treatment should be initiated promptly in cases with neurological or ocular involvement [16]. Supportive care (fluid therapy, nutritional support) is often necessary [16].

Prevention of Fecal Shedding and Zoonotic Transmission

Prevention strategies target both the cat and the environment. Key measures include:

• Litter box management: Daily removal of feces prevents oocyst sporulation (oocysts require 1-5 days to become infectious) [4, 11]. Litter boxes should be cleaned with hot water (>70°C) and disinfected with ammonia or 10% bleach solution [4].
• Indoor confinement: Keeping cats indoors reduces hunting and ingestion of infected prey, thereby preventing primary infection and subsequent shedding [9, 3].
• Dietary precautions: Feeding commercially processed cat food or cooked meat eliminates tissue cyst transmission [9, 3].
• Environmental hygiene: Covering sandboxes and garden soil prevents cat defecation in areas where humans may contact contaminated soil [4, 11].
• Pregnant and immunocompromised individuals: Seronegative pregnant women and immunocompromised persons should avoid handling cat litter or adopt strict hygiene measures (gloves, hand washing) [14, 23, 11]. Routine serological screening of cats is not recommended for human risk assessment because seropositive cats are unlikely to be actively shedding [9, 3].

Vaccination

No commercially available vaccine for feline toxoplasmosis currently exists. However, research into gene-edited live-attenuated vaccines and mRNA-based approaches is advancing [24, 25]. These vaccines aim to induce protective immunity that prevents oocyst shedding and tissue cyst formation [24, 25]. One Health strategies integrating veterinary and human vaccine development are under investigation [25].

Conclusion

Toxoplasmosis in cats remains a significant zoonotic concern due to the environmental contamination with oocysts shed in feces. Understanding the parasite's life cycle, epidemiology, and clinical manifestations is essential for veterinary practitioners. Diagnosis requires a combination of serology, PCR, and histopathology. Prevention focuses on reducing oocyst shedding through management practices and protecting at-risk human populations. Ongoing research into vaccines and improved diagnostics will further enhance control of this ubiquitous parasite.

References

[1] Sena F, Hakimi M-A, Francia ME. Proliferating toward sex: characterization of cell division of Toxoplasma gondii's pre-sexual stages. mBio. 2026. https://pubmed.ncbi.nlm.nih.gov/42153709/

[2] Alrubaye HS, Reilly SM, da Silva R, et al. A single-cell atlas of Toxoplasma sexual development in the feline intestinal tract. Nat Microbiol. 2026. https://pubmed.ncbi.nlm.nih.gov/42020723/

[3] Alkhatatbeh SK, Lafi SQ, Hammad HB, et al. The first seroprevalence and molecular detection of toxoplasmosis infecting cats in Jordan with associated risk factors. Vet Parasitol Reg Stud Reports. 2026. https://pubmed.ncbi.nlm.nih.gov/41741047/

[4] Eyre MT, Wang JY, Carneiro IO, et al. Social marginalisation, environmental degradation and Toxoplasma gondii exposure in urban informal settlements in Brazil. PLoS Negl Trop Dis. 2026. https://pubmed.ncbi.nlm.nih.gov/42330015/

[5] Muhammad AS, Kudi AC, Mohammed A, et al. Public health significance of prevalence and risk factors associated with Toxoplasma gondii infection in goats sampled from two quarantine facilities and an institutional farm in Maiduguri metropolis, Borno state, Nigeria. Sci Rep. 2026. https://pubmed.ncbi.nlm.nih.gov/42020619/

[6] Biswas PK, Aryal D, Tarak AN, et al. Genotype distribution and risk factors of Toxoplasma gondii infection in animals of Trishal, Bangladesh. PLoS One. 2026. https://pubmed.ncbi.nlm.nih.gov/41528989/

[7] Zhai B, Bao B, Xie SC, et al. Dynamic landscape of microRNA expression in the feline small intestine during Toxoplasma gondii infection. Parasit Vectors. 2026. https://pubmed.ncbi.nlm.nih.gov/41965856/

[8] Kengradomkij C, Chimnoi W, Kamyingkird K, et al. PCR detection of Toxoplasma gondii DNA in fecal samples from stray cats in Bangkok Metropolitan, Thailand. Food Waterborne Parasitol. 2026. https://pubmed.ncbi.nlm.nih.gov/42094705/

[9] Elsohaby I, Zubair M, Baqar Z, et al. Seroprevalence of Toxoplasma gondii and associated demographic factors in privately-owned dogs, cats, and community cats in Hong Kong. BMC Vet Res. 2026. https://pubmed.ncbi.nlm.nih.gov/42135800/

[10] Spada E, Tattarletti G, Proverbio D, et al. The AB Blood Group System Phenotype Does Not Play a Role in Toxoplasma gondii Infection in Cats. Pathogens. 2025. https://pubmed.ncbi.nlm.nih.gov/41471183/ *** Disclaimer: This article is for educational and informational purposes only. It is not intended to substitute for professional veterinary advice, diagnosis, treatment, or regulatory guidance. Always consult a licensed veterinarian or qualified specialist regarding animal health, disease diagnosis, and therapeutic decisions.

[11] Gharbi M, Yera H, Dupouy-Camet J. [The cat, the women and the toxoplasma: What advice should be given to a pregnant woman who is seronegative for toxoplasmosis and owns a cat?]. Gynecol Obstet Fertil Senol. 2026. https://pubmed.ncbi.nlm.nih.gov/41628830/

[12] de Velasco-Reyes I, Torres-García SE, Hernández-Rangel JJ, et al. Seroprevalence of Toxoplasma gondii Infection in Veterinary Medicine Professionals and Students in Aguascalientes, Mexico. Epidemiologia (Basel). 2026. https://pubmed.ncbi.nlm.nih.gov/42201205/

[13] Chalabi KN, Jabar Bakr E. Toxoplasmosis - knowledge among university students in Erbil, Iraq: a cross-sectional study. Int J Environ Health Res. 2026. https://pubmed.ncbi.nlm.nih.gov/41873025/

[14] Karacali B, Mor N. Investigation of anti-Toxoplasma gondii antibody seropositivity and possible risk factors in women with abortion or stillbirth history in Kars, Turkey. Afr J Reprod Health. 2026. https://pubmed.ncbi.nlm.nih.gov/42202767/

[15] Mihaljević D, Sitaš Z, Hanulak J, et al. Cerebral Toxoplasmosis in a Renal Transplant Recipient-A Rare Complication. Life (Basel). 2026. https://pubmed.ncbi.nlm.nih.gov/41900989/

[16] Doyle E, Walker J. Diagnosis of pyogranulomatous and neutrophilic lymphadenitis in 72 cats presenting to a referral hospital: with a focus on nine cats with steroid-responsive lymphadenitis. J Feline Med Surg. 2026. https://pubmed.ncbi.nlm.nih.gov/41527158/

[17] Jesuthasan J, Merritt K, Solmi F, et al. The association between childhood Toxoplasma gondii, psychotic experiences and grey matter volume: A population-based cohort study. Schizophr Res. 2026. https://pubmed.ncbi.nlm.nih.gov/41643571/

[18] Loeb J. Thrill seekers: how parasites change host behaviour. Vet Rec. 2026. https://pubmed.ncbi.nlm.nih.gov/41481062/

[19] Askaryanzardak A, Kakkassery V, Tartaglione Gracia GP, et al. [Ocular toxoplasmosis in adults : Refresher course]. Ophthalmologie. 2026. https://pubmed.ncbi.nlm.nih.gov/41603939/

[20] Mu X, Chen C, Pu X, et al. Development and Field Validation of a Double-Antigen Sandwich Colloidal Gold Immunochromatographic Strip for Detection of Toxoplasma gondii Antibodies in Multiple Host Species. Transbound Emerg Dis. 2026. https://pubmed.ncbi.nlm.nih.gov/42253330/

[21] Chen XX, Sun H, Liang Y, et al. Development of a SAG1-based colloidal gold immunochromatographic strip for rapid serological detection of swine Toxoplasma gondii. Parasit Vectors. 2026. https://pubmed.ncbi.nlm.nih.gov/42169035/

[22] Li YY, Bai SY, Yu HQ, et al. Development and evaluation of an antisense PCR assay for Toxoplasma gondii detection in domestic cats. Vet Parasitol. 2026. https://pubmed.ncbi.nlm.nih.gov/41724116/

[23] Henriette BA, Jémima EK, Jean-Sébastien MA, et al. First report of knowledge and practices towards toxoplasmosis among pregnant women in primary care in Abidjan, Côte d'Ivoire. Trop Parasitol. 2026. https://pubmed.ncbi.nlm.nih.gov/42199683/

[24] Sang X, Zhang H, Zhang Y, et al. Gene-edited live-attenuated vaccines against Toxoplasma gondii: recent advances and future frontiers. Parasit Vectors. 2026. https://pubmed.ncbi.nlm.nih.gov/42252477/

[25] Qadeer A, Tharwat M, Khan MZ, et al. Advances and Translational Challenges in Toxoplasma gondii Vaccine Development: From Antigen Discovery to mRNA and One Health Strategies. Vet Sci. 2026. https://pubmed.ncbi.nlm.nih.gov/42188907/

[26] Pinto GOA, Silva RAD, Oliveira PRF, et al. Molecular detection of Toxoplasma gondii in an aborted equine fetus and serological evidence of infection in mares enrolled in embryo transfer programs in Brazil. J Equine Vet Sci. 2026. https://pubmed.ncbi.nlm.nih.gov/42252005/

[27] Aziz KJ, Mikaeelb FB, Nasrullah OJ, et al. Seroepidemiological investigation of Toxoplasma gondi and Neospora caninum in local Deers in Erbil, Iraq. Vet Parasitol Reg Stud Reports. 2026. https://pubmed.ncbi.nlm.nih.gov/42034957/

[28] Orish VN, Tetteh RE, Adzah D, et al. Toxoplasma gondii seropositivity among patients with sickle cell disease: Prevalence and association with blood transfusion history. PLoS One. 2026. https://pubmed.ncbi.nlm.nih.gov/41931585/

[29] Günay-Esiyok Ö, Koçkaya ES, Yılmaz R, et al. The Potential of MIC17A both as an Entero-epithelial and Chronic Stage Marker for Detection of Feline Toxoplasmosis. Curr Microbiol. 2026. https://pubmed.ncbi.nlm.nih.gov/41874672/

[30] Ait Issad N, Mohamed Cherif A, Mebkhout F, et al. First report of molecular and histopathological detection of Toxoplasma gondii in aborted fetal goat myocardium in Algeria with associated risk factors. Parasitol Int. 2026. https://pubmed.ncbi.nlm.nih.gov/41864556/

[31] Artiaga-Silva GL, de Lima Ruy Dias ÁF, Carvalho MR, et al. High Seroprevalence Rates of Toxoplasma gondii and Neospora caninum in Dogs in the Pantanal Region of Mato Grosso, Brazil. Acta Parasitol. 2026. https://pubmed.ncbi.nlm.nih.gov/41843222/

[32] Hanedan B, Taş BZ, Yıldırım E, et al. Investigation of Toxoplasma gondii seroprevalence and associated risk factors in dairy cattle in the Eastern Anatolia region of Türkiye. Vet Parasitol Reg Stud Reports. 2026. https://pubmed.ncbi.nlm.nih.gov/41819961/

[33] Marín-García PJ, Ballesteros-García O, Martínez-Sáez L, et al. Low seroprevalence of Toxoplasma gondii in pig farms (Sus scrofa domesticus) of eastern Spain in intensive farms with control of animal entry. Vet Parasitol Reg Stud Reports. 2026. https://pubmed.ncbi.nlm.nih.gov/41741032/

[34] Murata FHA, Barboza JP, de Souza CAG, et al. Investigation of Toxoplasma gondii in reproductive tissues of companion animals from a municipal neutering program. Vet Parasitol Reg Stud Reports. 2026. https://pubmed.ncbi.nlm.nih.gov/41651631/

[35] Filho SCC, Moron SE, Ferreira RG, et al. Risk Factors and Ocular Health Associated with Toxoplasmosis in Quilombola Communities. Microorganisms. 2026. https://pubmed.ncbi.nlm.nih.gov/41597614/